European stocks trading in the US as American depositary receipts (ADRs) were nearly flat Tuesday morning, with the S&P Europe Select ADR Index edging up just 0.07% to 1,884.21. The modest move masked a wide divergence beneath the surface: advertising giant WPP and oil major BP provided the lift, while a cluster of biotech names, including BioNTech, dragged the index down.
What are ADRs and why do they matter?
ADRs are shares of foreign companies that trade on US exchanges, allowing American investors to buy stakes in overseas firms without dealing with foreign currencies or cross-border brokerage accounts. Each ADR represents a certain number of the company's underlying shares, and its price moves in tandem with the home-market stock. The S&P Europe Select ADR Index tracks a basket of these instruments, giving a snapshot of how European equities are performing in US trading.
For everyday investors, ADRs are a convenient way to diversify internationally. They also offer a window into how global markets are reacting to the same news that moves US stocks, such as interest rate expectations, corporate earnings, and geopolitical events.
WPP and BP lead the way
WPP, the London-based advertising and public relations firm, jumped 5.2% on Tuesday. The company is one of the world's largest marketing services groups, and its shares often react to changes in corporate spending on advertising and brand promotion. A gain of that size suggests investors were encouraged by something specific to the company or the sector, though the brief does not detail the cause.
BP, the British oil and gas giant, rose 3.8%. Energy stocks have been sensitive to crude oil prices, which have been volatile recently. A rise in BP's ADR could reflect higher oil prices or a broader rally in energy shares. For investors, BP's performance is a reminder that commodity prices can have a direct impact on the profitability of energy producers.
Biotech drag: BioNTech and others fall
On the losing side, BioNTech, the German biotech that became a household name during the pandemic for its COVID-19 vaccine, fell 6%. Other drug developers, including Evaxion and Autolus, also dropped sharply. Biotech stocks are known for their volatility, as their valuations often hinge on clinical trial results, regulatory decisions, and pipeline updates. A single piece of news can send a stock swinging by double digits.
The declines in biotech were enough to offset the gains from WPP and BP, leaving the overall index nearly unchanged. This is a classic example of how index math works: a broad basket can appear calm when winners and losers cancel each other out, even if individual components are moving sharply.
What it means for investors
For investors holding European ADRs, Tuesday's action underscores the importance of looking beyond the headline index number. A flat index can hide significant moves in specific sectors or companies. If you own a diversified portfolio of European ADRs, a day like this might not move the needle much. But if you are concentrated in biotech or energy, the swings could be more pronounced.
The performance of European ADRs also reflects broader trends in the global economy. Europe has been grappling with slower growth, high energy costs, and the impact of China's economic slowdown, which has hit luxury goods and other sectors. Meanwhile, the US Federal Reserve's interest rate policy continues to influence global markets, as higher US yields can attract capital away from other regions.
For those watching the energy sector, BP's gain may be a sign that oil prices are finding support. For biotech investors, the sharp drops in BioNTech and others serve as a reminder of the sector's risk profile. As always, diversification remains a key strategy for managing such volatility.
Looking ahead
Investors will be watching to see whether the divergence between winners and losers persists. The broader European market has been under pressure from concerns about the Chinese economy and the pace of interest rate hikes by the European Central Bank. At the same time, some sectors, like energy and advertising, may benefit from resilient consumer spending and corporate budgets.
For now, the S&P Europe Select ADR Index's tiny gain suggests that European equities are treading water, with no clear direction. That could change quickly if new economic data or corporate earnings surprise to the upside or downside. As always, keeping an eye on the underlying drivers—oil prices, central bank policy, and company-specific news—will be key to understanding where European ADRs head next.
Related: European stocks edge up as oil cools, but chip fears hit tech and China's slowdown hits Europe's luxury sector.
